732
Views
4
CrossRef citations to date
0
Altmetric
Editorials

Targeting proinsulin-reactive CD8+ T cells: a new direction for Type 1 diabetes treatment

&
Pages 1001-1004 | Published online: 10 Jan 2014
 

Financial & competing interests disclosure

The authors are supported by grants from the Juvenile Diabetes Research Foundation, the Dutch Diabetes Research Foundation, The Netherlands Organization for Health Research and Development (ZonMW: VICI award) and the European Union (EU-FP7 Framework, NAIMIT, BetaCellTherapy & EE-ASI). BO Roep has consulted for Diamyd Medical, Andromeda Biotech, Novo Nordisk AS, GSK and Lilly and received financial support for mechanistic studies from Bayhill Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.